NCT06143423终止1 期
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate AP026 (TQA2226) for Injection in Adult Subjects After Single/Multiple Administration.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2023年5月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Incidence of serious adverse events (SAEs)
研究概览
简要总结
This study was a randomized, double-blind, placebo-controlled phase I clinical trial of AP026 (TQA2226) for injection in adult healthy subjects, which planned to recruit 74 healthy subjects. The main purpose was to evaluate the safety and tolerance of AP026 (TQA2226) for injection after single and multiple doses in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Sign an informed consent form before the study and have a thorough understanding of the content, process, and potential adverse reactions of the study;
- •Able to complete the study according to the requirements of the protocol;
- •Subjects (including their partners) are willing to voluntarily take effective contraceptive measures within 6 months after the last study drug administration;
- •Male and female subjects aged 18-55 (inclusive);
- •Male subjects weighing no less than 50 kilograms and female subjects weighing no less than 45 kilograms, With a body mass index within the range of 18~28kg/m2 (inclusive);
- •Physical examination and vital signs are normal or abnormal but with no clinical significance (judged by the investigators).
排除标准
- •Pregnant and lactating women;
- •There are abnormal and clinically significant clinical laboratory examination results, or clinically significant diseases within 12 months before screening, which is not recommended to participate in the trial after evaluation by the investigators. Subjects with a previous medical history but are recovered with clinical evidence can be included in this study;
- •During the screening period, any one of the vital signs, physical examination, laboratory examination, 12 lead electrocardiogram, and other auxiliary examination results is abnormal and judged by the investigator to have clinical significance;
- •Subjects who test positive for any of the hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (Anti HCV), human immunodeficiency virus antibody (Anti HIV), and Treponema pallidum antibody (Anti TP);
- •Those who have undergone surgery within 4 weeks before screening or plan to undergo surgery during the study period;
- •Received investigational drugs or participated in clinical trials within 3 months prior to screening;
- •Received immunoglobulin or blood products within 30 days before randomization;
- •Donated blood (> 300 mL) or experienced significant blood loss (> 400 mL) within 3 months prior to screening;
- •Subjects with a history of needle sickness, blood sickness, or potential difficult in collecting blood;
- •History of allergic reactions to other therapeutic monoclonal antibodies or biological agents, or history of allergies to multiple drugs or foods, especially to ingredients similar to the study drug;
- •Smoking more than 5 cigarettes per day or using an equivalent amount of nicotine or nicotine containing products within 3 months before randomization, or failing to stop using any tobacco products during the trial period;
- •Those who have been drinking excessively for a long time or have consumed more than 14 units of alcohol per week within 3 months before screening, or cannot abstain from alcohol during the trial period, or have tested positive for alcohol breath test;
- •Subjects with a history of drug abuse, or positive urine drug screening;
- •Received any commercially available or investigational biological agents within 4 months before randomization or within 5 half-lives of drugs (whichever is longer);
- •Within 4 weeks before randomization, received any systemic prescription drugs, over-the-counter drugs, herbs, any vitamin products, and health products, or any topical drugs of the above forms at the injection site of this study;
- •From the screening period to the study medication, acute diseases or concomitant medication occured.
- •Any medical history that may affect drug absorption, distribution, metabolism, and excretion.
- •Any situation that the investigator believes will pose a safety risk to the subject during the study or may interfere with the implementation of this study, or the investigator believes that the subject may not be able to complete this study or may not be able to comply with the requirements of this study.
- •QT interval > 450 milliseconds, or electrocardiogram is not suitable for Concentration-QT measurement (according to the judgment of the investigator).
- •History of risk factors for torsade de pointe ventricular tachycardia. Subject with a family history of long QT syndrome or Brugada syndrome will also be excluded.
- •Heart rate ≤ 45 bpm.
- •History of renal or liver dysfunction.
- •History or condition of cardiovascular disease.
研究组 & 干预措施
AP026 (TQA2226) for injection Single administration dose (SAD)
Experimental
AP026 (TQA2226) for injection, administered once.
干预措施: AP026 (TQA2226) for injection (Drug)
AP026 (TQA2226) for injection matching placebo Single administration dose (SAD)
Placebo Comparator
AP026 (TQA2226) for injection matching placebo, administered once.
干预措施: AP026 (TQA2226) for injection matching placebo (Drug)
AP026 (TQA2226) for injection Multiple administration dose (MAD)
Experimental
AP026 (TQA2226) for injection, administered 4 times.
干预措施: AP026 (TQA2226) for injection (Drug)
AP026 (TQA2226) for injection matching placebo Multiple administration dose (MAD)
Placebo Comparator
AP026 (TQA2226) for injection matching placebo, administered 4 times.
干预措施: AP026 (TQA2226) for injection matching placebo (Drug)
结局指标
主要结局
Incidence of serious adverse events (SAEs)
时间窗: From patient enrollment to withdrawal, estimated up to 2 months.
Incidence of serious adverse events after dose, assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.
Severity of serious adverse events (SAEs)
时间窗: From patient enrollment to withdrawal, estimated up to 2 months.
Severity of serious adverse events after dose, assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.
Incidence of adverse events (AEs)
时间窗: From patient enrollment to withdrawal, estimated up to 2 months.
Incidence of adverse events after dose, assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.
Severity of adverse events
时间窗: From patient enrollment to withdrawal, estimated up to 2 months.
Severity of adverse events after dose, assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.
次要结局
- Cmax, ss(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Cmin, ss(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- AUC, ss(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Rac(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Peak concentration (Cmax)(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Plasma concentration-area under time curve (AUC0-t)(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Plasma concentration-area under time curve (AUC0-∞)(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Peak Time (Tmax)(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Apparent volume of distribution (Vd/F)(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Clearance (CL)(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Elimination half-life time (t1/2)(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Plasma concentration at steady state (Cav, SS)(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Tmax, ss(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
- Anti-Drug Antibody (ADA)(SAD: From 30 minutes before administration to 1176 hours after administration on Day 1. MAD: From 30 minutes before administration on Day 1 to 1008 hours after the last administration.)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Evaluation of Dupilumab in Patients with Persistent Asthma (Liberty Asthma Quest)AsthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-004940-36-HUSanofi-aventis Recherche & Développement1,858
进行中（未招募）
1 期
Evaluation of Dupilumab in Patients with Persistent AsthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2014-004940-36-DESanofi-aventis Recherche & Développement1,858
进行中（未招募）
1 期
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Persistent AsthmaAsthmaEUCTR2014-004940-36-ITSanofi-aventis Recherche & Développement1,902
进行中（未招募）
1 期
Evaluation of Dupilumab in Patients with Persistent Asthma (Liberty Asthma Quest)AsthmaMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-004940-36-GBSanofi-aventis Recherche & Développement1,902
进行中（未招募）
1 期
Evaluation of Dupilumab in Patients with Persistent Asthma (Liberty Asthma Quest)AsthmaEUCTR2014-004940-36-PLSanofi-aventis Recherche & Développement1,858